PriceTargets.com logo

Greenwich LifeSciences - GLSI Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $42.00
  • Forecasted Upside: 377.27%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.80 As of 12/4/2025 05:00 PM ET
▲ +0.39 (4.64%)

This chart shows the closing price for GLSI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Greenwich LifeSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLSI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLSI

Analyst Price Target is $42.00
▲ +377.27% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Greenwich LifeSciences in the last 3 months. The average price target is $42.00, with a high forecast of $45.00 and a low forecast of $39.00. The average price target represents a 377.27% upside from the last price of $8.80.

This chart shows the closing price for GLSI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Greenwich LifeSciences. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/14/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/20/2025Noble FinancialInitiated CoverageOutperform$45.00
4/21/2025HC WainwrightBoost TargetBuy ➝ Buy$38.00 ➝ $39.00
2/11/2025HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
8/23/2024HC WainwrightBoost TargetBuy ➝ Buy$36.00 ➝ $38.00
5/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00
2/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00
2/20/2024HC WainwrightLower TargetBuy ➝ Buy$38.00 ➝ $36.00
4/10/2023HC WainwrightLower TargetBuy$78.00 ➝ $38.00
12/7/2021HC WainwrightReiterated RatingBuy$78.00
9/1/2021HC WainwrightInitiated CoverageBuy$78.00
1/26/2021AegisInitiated CoverageBuy$75.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.17 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 1 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
Mentions as of
10/5/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
11/4/2025
  • 10 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 10 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Greenwich LifeSciences logo
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Read More

Today's Range

Now: $8.80
Low: $8.30
High: $8.85

50 Day Range

MA: $9.23
Low: $7.85
High: $11.44

52 Week Range

Now: $8.80
Low: $7.78
High: $14.47

Volume

46,671 shs

Average Volume

70,720 shs

Market Capitalization

$121.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Greenwich LifeSciences?

The following Wall Street sell-side analysts have issued reports on Greenwich LifeSciences in the last twelve months: HC Wainwright, Noble Financial, and Weiss Ratings.
View the latest analyst ratings for GLSI.

What is the current price target for Greenwich LifeSciences?

0 Wall Street analysts have set twelve-month price targets for Greenwich LifeSciences in the last year. Their average twelve-month price target is $42.00, suggesting a possible upside of 377.3%. Noble Financial has the highest price target set, predicting GLSI will reach $45.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $39.00 for Greenwich LifeSciences in the next year.
View the latest price targets for GLSI.

What is the current consensus analyst rating for Greenwich LifeSciences?

Greenwich LifeSciences currently has 1 sell rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GLSI, but not buy more shares or sell existing shares.
View the latest ratings for GLSI.

What other companies compete with Greenwich LifeSciences?

Other companies that are similar to Greenwich LifeSciences include Zevra Therapeutics, Lyell Immunopharma, DBV Technologies, Evolus and SNDL. Learn More about companies similar to Greenwich LifeSciences.

How do I contact Greenwich LifeSciences' investor relations team?

The company's listed phone number is 832-819-3232 and its investor relations email address is [email protected]. The official website for Greenwich LifeSciences is www.greenwichlifesciences.com. Learn More about contacing Greenwich LifeSciences investor relations.